Biblio
Deepening Responses Post Upfront ASCT in Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy. Transplant Cell Ther. 2022.
Multicentric Castleman disease - a single center experience of treatment with a focus on autologous stem cell transplantation. Am J Hematol. 2022.
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. Blood Adv. 2023;7(16):4371-4380.